HILLEVAX INC. - COMMO

HilleVax Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress

07 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

08 Aug 2024 18:20:24 By Nasdaq GlobeNewswire

HilleVax Announces Reduction in Force

31 Jul 2024 15:00:00 By Nasdaq GlobeNewswire

HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants

08 Jul 2024 06:30:00 By Nasdaq GlobeNewswire

HilleVax Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

09 May 2024 15:05:00 By Nasdaq GlobeNewswire

HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress

20 Mar 2024 15:00:00 By Nasdaq GlobeNewswire

HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer

18 Jan 2024 06:00:00 By Nasdaq GlobeNewswire

HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China

08 Jan 2024 06:00:00 By Nasdaq GlobeNewswire

HilleVax to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 Jan 2024 17:28:04 By Nasdaq GlobeNewswire

HilleVax Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

09 Nov 2023 15:05:01 By Nasdaq GlobeNewswire

HilleVax to Present at Upcoming Investor Conferences

01 Nov 2023 15:48:37 By Nasdaq GlobeNewswire

HilleVax to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference

26 Sep 2023 15:01:00 By Nasdaq GlobeNewswire

HilleVax Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

25 Sep 2023 06:00:00 By Nasdaq GlobeNewswire

HilleVax Announces Pricing of Public Offering of Common Stock

19 Sep 2023 19:05:50 By Nasdaq GlobeNewswire

HilleVax Announces Proposed Public Offering of Common Stock

19 Sep 2023 15:09:25 By Nasdaq GlobeNewswire

HilleVax Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

14 Aug 2023 06:00:01 By Nasdaq GlobeNewswire

HilleVax Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

12 May 2023 15:05:00 By Nasdaq GlobeNewswire

HilleVax Announces Appointment of Nanette Cocero Ph.D., MBA, to its Board of Directors

09 May 2023 06:00:01 By Nasdaq GlobeNewswire

HilleVax Announces Completion of Enrollment of NEST-IN1 Phase 2b Clinical Study of HIL-214 Norovirus Vaccine Candidate

25 Apr 2023 05:45:00 By Nasdaq GlobeNewswire

HilleVax Reports Full Year 2022 Financial Results and Highlights Recent Company Progress

17 Mar 2023 15:05:00 By Nasdaq GlobeNewswire